{"id":3753,"date":"2022-04-28T05:23:57","date_gmt":"2022-04-28T09:23:57","guid":{"rendered":"https:\/\/clariowebstg.wpengine.com\/?post_type=therapeutic-areas&p=3753"},"modified":"2025-09-16T08:40:27","modified_gmt":"2025-09-16T12:40:27","slug":"hepatology","status":"publish","type":"therapeutic-areas","link":"https:\/\/clario.com\/therapeutic-areas\/hepatology\/","title":{"rendered":"Hepatology"},"content":{"rendered":"
\n
\n \n
\n\t\n\n
\n\t\t\t\n\n

State-of-the-art NAFLD\/NASH assessment<\/h2>\n\n\n\n

Clario\u2019s therapeutic expertise and our best-in-class image analysis and systems<\/a> provide you with comprehensive Non-Alcoholic Fatty Liver Disease (NAFLD)\/Non-Alcoholic Steatohepatitis (NASH) clinical trial management and study support \u2014 from start to finish.<\/p>\n\n\n\n

When combined with clinical data, our non-invasive imaging techniques expedite the assessment of disease severity and provide you with a more accurate picture of disease changes. Through our understanding of the complexities of NAFLD\/NASH endpoints, our liver clinical trial management experts can help you customize a biomarker and imaging package specific to your trial\u2019s goals and objectives.<\/p>\n\n\t<\/div>\n\n<\/div>\n\n\n

\n\t\n\n
\n\t\t\t\n\n

Changing the way liver disease is monitored<\/h2>\n\n\n\n

Surgical biopsy, the current diagnostic standard, is invasive, expensive, and painful. Biopsies also only provide information from just a small part of the liver, so relying on biopsies alone can often delay diagnosis and treatment \u2014 often until cirrhosis or liver cancer is present. At Clario, our liver clinical trial team utilizes advanced medical imaging to provide important, quantitative information on liver changes in NAFLD\/NASH patients \u2014 useful data to help inform patient eligibility and to determine drug efficacy.<\/p>\n\n\t<\/div>\n\n<\/div>\n\n <\/div>\n<\/div>\n\n\n

\n
\n \n
\n\t\n\n
\n\t\t\t\n\n

Hepatology experience<\/h2>\n\n\t<\/div>\n\n<\/div>\n\n\n
\n\t\n\n
\n\t\t\t\n
\"\"

55+<\/p>

Liver\/Muscle Dixon studies<\/p><\/div>

\"\"

20+<\/p>

Liver studies with MRI-PDFF, MR Elastography and SAT\/VAT depot analysis<\/p><\/div>

\"\"

320+<\/p>

Study sites<\/p><\/div>

\"\"

2,225+<\/p>

Magnetic resonance imaging. Proton density fat fraction (MRI-PDFF) analyses<\/p><\/div>

\"\"

750+<\/p>

MR elastography (MRE) analyses<\/p><\/div>

\"\"

600+<\/p>

SAT\/VAT segmentation<\/p><\/div><\/div>\n\t<\/div>\n\n<\/div>\n\n <\/div>\n<\/div>\n\n\n

\n
\n \n
\n\t\n\n
\n\t\t\t\n\n

Improving enrollment and retention with timely image reads that are right the first time<\/h2>\n\n\n\n